Home › Compare › CYAD vs XYLD

CYAD vs XYLD: Dividend Comparison 2026

CYAD yields 425.53% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYAD wins by $18058.57M in total portfolio value
10 years
CYAD
CYAD
● Live price
425.53%
Share price
$0.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18058.60M
Annual income
$12,349,610,253.13
Full CYAD calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — CYAD vs XYLD

📍 CYAD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYADXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYAD + XYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CYAD pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYAD
Annual income on $10K today (after 15% tax)
$36,170.21/yr
After 10yr DRIP, annual income (after tax)
$10,497,168,715.16/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, CYAD beats the other by $10,497,165,978.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYAD + XYLD for your $10,000?

CYAD: 50%XYLD: 50%
100% XYLD50/50100% CYAD
Portfolio after 10yr
$9029.31M
Annual income
$6,174,806,736.07/yr
Blended yield
68.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CYAD right now

CYAD
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Altman Z
-41.9
Piotroski
2/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYAD buys
0
XYLD buys
0
No recent congressional trades found for CYAD or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYADXYLD
Forward yield425.53% ✓10.98%
Annual dividend / share$2.00$4.30 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$18058.60M ✓$25.3K
Annual income after 10y$12,349,610,253.13 ✓$3,219.02
Total dividends collected$17541.95M ✓$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: CYAD vs XYLD ($10,000, DRIP)

YearCYAD PortfolioCYAD Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$53,253$42,553.19$10,818$1,098.39+$42.4K → CYAD
2$268,765$211,784.42$11,738$1,222.51+$257.0K → CYAD
3$1,286,515$998,936.38$12,774$1,364.64+$1.27M → CYAD
4$5,845,421$4,468,849.76$13,944$1,527.86+$5.83M → CYAD
5$25,230,957$18,976,356.52$15,270$1,715.87+$25.22M → CYAD
6$103,547,438$76,550,313.71$16,775$1,933.09+$103.53M → CYAD
7$404,404,397$293,608,638.27$18,490$2,184.87+$404.39M → CYAD
8$1,504,383,912$1,071,671,207.21$20,450$2,477.63+$1504.36M → CYAD
9$5,335,499,864$3,725,809,078.26$22,697$2,819.19+$5335.48M → CYAD
10$18,058,595,107$12,349,610,253.13$25,280$3,219.02+$18058.57M → CYAD

CYAD vs XYLD: Complete Analysis 2026

CYAD — Stock

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Full CYAD Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this CYAD vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYAD vs SCHDCYAD vs JEPICYAD vs OCYAD vs KOCYAD vs MAINCYAD vs QYLDCYAD vs JEPQCYAD vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.